linjc16/ctgov huggingface dataset:
Weight Gain in Surgically Treated Adult-onset Craniopharyngioma

Study Overview
=================
Brief Summary
-----------------
The aim of the study was to describe postoperative weight change in adults undergoing surgery for craniopharyngioma and identify preoperative factors associated with it.

Detailed Description
-----------------
Morbid obesity, intractable weight gain due to hypothalamic damage, is a common and troubling complication in patients undergoing surgery for craniopharyngioma combined or not with radiotherapy, with an incidence of 23 62% in pediatric patients. It has a major negative impact on metabolic and cardiovascular health and quality of life in long-term survivors. Identifying patients at higher risks for developing postoperative weight gain is of great importance in preventing obesity and taking early actions in this population. Though a lot of previous studies have been made in pediatric patients and several factors, such as hypothalamic involvement, higher body mass index (BMI) standard deviation score (SDS) at diagnosis, age at diagnosis and hydrocephalus requiring a shunt, have been identified as risk factors for postoperative weight gain, data on this important morbidity in adult-onset patients are sparse, especially in Chinese population. Therefore, the investigators are going to undertake a retrospective evaluation of postoperative weight change in adult-onset patients undergoing surgery for craniopharyngioma and identify preoperative factors associated with it.

Official Title
-----------------
Weight Gain in Surgically Treated Adult-onset Craniopharyngioma

Conditions
-----------------
Adult-onset Craniopharyngioma, Postoperative Weight Gain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult-onset, aged 18 years or more; pathologically confirmed craniopharyngioma; primary surgery performed at our hospital; at least 3 months of follow-up including body weight measurement; ambulatory (since lack of ambulation may predispose to weight gain); not receiving supraphysiologic doses of glucocorticoid (e.g. hydrocortisone, prednisone, or dexamethasone to exceed 12mg/m2•d hydrocortisone equivalent) for more than 2 months after tumor therapy. Exclusion Criteria: Childhood-onset, <18 years old; Inconsistent pathology; Without follow-up records in the investigators' institution.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 81 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of postoperative weight gain |  | 2.5 years |
Elite Sport and Development of Asthma

Study Overview
=================
Brief Summary
-----------------
International studies have shown that elite athletes have a high prevalence of respiratory symptoms and asthma as compared to normal subjects. It is unclear whether the increased prevalence of asthma in elite athletes reflects traditional asthma or whether it is a special form of sports asthma. The treatment of elite athletes with asthma seems to vary widely, and only a few studies have focused on the treatment of elite athletes with asthma. Further knowledge of the pathogenesis of sports asthma would lead to a greater understanding and better treatment of the condition. This study will investigate the type of airway inflammation in elite athletes and examine the effect of treatment with inhaled steroids in combination with long-acting beta-agonists versus placebo in the same group.

Official Title
-----------------
Elite Sport and Development of Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Seretide
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elite athletes Informed consent Doctor diagnosed asthma Exclusion Criteria: Current smoker or more than 10 pack-years Pregnancy, breast feeding or planning pregnancy during the study. ICS within the last 4 weeks prior to visit 1.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Placebo inhaler (sugar powder) | Drug: Placebo<br>* Inhaled sugar powder in a placebo inhaler<br>|
| Active Comparator: Seretide<br>Seretide inhaler | Drug: Seretide<br>* Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eucapnic voluntary hyperventilation (EVH) |  | End of study | 
| Exhaled Nitric Oxide |  | End of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory symptoms |  | End of study | 
| Lung function |  | End of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sport, Asthma, Treatment, Airway inflammation
Study of Microbiota in Longevity County, Yongfu

Study Overview
=================
Brief Summary
-----------------
This study is an observational study designed to adopt a cross-sectional study design. In the context of China's longevity town (East Asian population), Yongfu, Guangxi, the background of non-medical care and antibiotic use was explored, and the intestinal microecological balance increased with age and natural health. Longevity relationship. This study was completed using a household survey. Through routine clinical examinations and analysis of biochemical laboratory indicators, at the same time, a questionnaire for ADL(activities of daily living), cognitive function, and related elderly information was carried out on the elderly to comprehensively provide health information for each elderly. Based on the remaining stool samples and serum samples, the second-generation sequencing technology and other omics-based technologies were explored. No additional collection of human specimens and information is involved. In addition, this study also hopes to explore the transmission rules of age-related bacteria in long-lived families, and the relationship with health phenotypes such as blood sugar, blood lipids, and cognitive function. Potential impact. In summary, this study will provide data support for exploring the relationship between healthy longevity and intestinal microecological balance based on the characteristic population of the longevity hometown.

Official Title
-----------------
Study of the Feature of Intestinal Microbiota and Its Role in Healthy Aging in Southern Chinese From a Longevity County, Yongfu

Conditions
-----------------
Aging, Healthy Aging

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obtained informed consent signed by volunteer or guardian Local lived for more than 50 years Exclusion Criteria: Subjects being treated with antibiotic in 3 months People who cannot cooperate with completing the survey Severe gastrointestinal disorders

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 111 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aging-related fecal microbiota annotation | Taxonomy of bacteria(family,genus,species),Gene of bacteria | 0 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| interface of microbiota and other biomarkers in aging and related conditions | to study the correlation between microbiota and circulating biomarkers, including metabolite, and the shifts in various aging and related conditions | 0 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Microbiota, multi-omics
How Acupuncture Sensation Propagated to Effect the Energy of Channels

Study Overview
=================
Brief Summary
-----------------
De-qi as an important factor to therapeutic effect of acupuncture for years, It's a concrete pathway to approach Qi, an abstract concept in Chinese medicine. However, all previous physicians and medical scientists have different interpretation to De-qi, and no objective principles for clinical practice, teaching and studies. Qi propagated combined with acupuncture practice always be seen as De-qi , therefore, the study control transmission or not and direction of sensation propagated to compare what's different in human body. If the change happened as prediction based on acupuncture theories, it could define De-qi for operation. The study will collect 60 subjects, from age 20 to 40, the same numbers of male and female. They will accept different manipulation in left hand HeGu(LI4), and assessed the variations in microcirculation, temperature of left forearm, and waxing/waning of yin-yang , Qi and blood in related meridian. We hope to understand if sensation propagated is primary factor of De-Qi and acupuncture effect .

Conditions
-----------------
Acupuncture Manipulation

Intervention / Treatment
-----------------
* Device: acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: both male and female age:20-40 years old Exclusion Criteria: to be afraid of acupuncture easily fainting right index finger has been injured recent one month had taken drugs can trigger vasodilatation or vasoconstriction recent three months systemic diseases pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: acupuncture<br>acupuncture manipulation | Device: acupuncture<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| variation trend of electric conductivity |  | 30-60seconds per trial | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood flow speed |  | 30-60seconds per trial |
Use of the VasoNova VPS System During PICC Placement in an Algorithm Confirmation Study Using Fluoroscopy

Study Overview
=================
Brief Summary
-----------------
Subjects meeting study requirements will be consented and have their PICC catheter placed using navigational technology and the tip placement confirmed with radiographic imaging.

Official Title
-----------------
Use of the VasoNova VPS System During PICC Placement in an Algorithm Confirmation Study Using Fluoroscopy

Conditions
-----------------
Any Condition Requiring a PICC Placement

Intervention / Treatment
-----------------
* Device: VPS System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult with a PICC placement order Exclusion Criteria: Pregnant or nursing Abnormal ECG Anatomic irregularities or history that would prevent proper placement Subject does not consent to photography, release of data and x-ray confirmation Subject does not understand or is not willing to sign informed consent for the VPS implant procedure and data release

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VPS System<br>Use of navigational VPS system to place catheter | Device: VPS System<br>* Use of the navigational VPS system during catheter placement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance target: the catheter tip will be located in the lower 1/3 of the SVC or at the cavoatrial junction as evaluated by fluoroscopy with a VPS bullseye at least 90% of the time |  | participants are followed until catheter tip confirmation via fluoroscopy is completed which is on average one hour from procedure initiation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The VPS will provide a blue bullseye indicator 80-90% of the time |  | participants are followed until catheter tip confirmation is completed which is on average one hour from the start of the procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PICC
Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension

Study Overview
=================
Brief Summary
-----------------
Aldazide 25 mg OD will be given to Filipino hypertensive patients, and there will be 2 follow-up visits on week 4 and week 8 to monitor for safety and efficacy as primary and secondary outcomes, respectively.

Detailed Description
-----------------
Prospective, non-interventional non-probability sampling

Official Title
-----------------
An Open Label, Observational, Post Marketing Surveillance Study To Assess The Safety And Efficacy Of The Spironolactone Plus Hydroflumethiazide (Aldazide) In The Treatment Of Filipino Patients With Stage 1 To 2 Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Aldazide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients >/= 18 years old with Stage 1 or 2 hypertension not controlled by monotherapy or by a combination of anti-hypertensives without any diuretic yet. Exclusion Criteria: Pregnant or lactating women, with hypersensitivity to Aldazide, patients with resistant hypertension not controlled by a combination therapy with a diuretic in their regimen

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Aldazide|Aldazide 25 mg OD|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Report of Adverse Events occurence (Safety) |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systolic BP in mmHg |  | 8 weeks | 
| Diastolic BP in mmHg |  | 8 weeks | 
| % of patients reaching BP goal of <140/90 mmHg and <130/80 mmHg for DM and proteinuric patients |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spirinolactone, Hydroflumethiazide, Hypertension, Filipinos, Diabetes mellitus, Proteinuria
Pharmacokinetics of Resveratrol Comprising Products

Study Overview
=================
Brief Summary
-----------------
This study was designed to assess the pharmacokinetics of 2 doses of Red Grape Cells (RGC) containing resveratrol compared with a reference. RGC will be administered as single oral dose to fasting healthy volunteers. Plasma concentration of free resveratrol and total conjugates will be analyzed.

Official Title
-----------------
Randomized Three-way Cross-over Comparative Pharmacokinetic Study of Resveratrol Comprising Products in Fasting Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: RGC
* Dietary Supplement: RGC
* Dietary Supplement: Resveratrol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 18-55 years; BMI >/= 19 and </= 30 non smoking without history or evidence of significant cardiovascular, hepatic, renal, respiratory, gastrointestinal disease normal physical and laboratory examinations Exclusion Criteria: History or evidence of alcohol or drug abuse subjects receiving chronic medication unusual dietary habits or a recent change in body weight acute medical situation 48 hours prior to initiation of the study poor venous access Subjects participated in a trial or donated blood within 4 weeks before initiation of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RGC1<br>RGC containing the equivalent of 50 mg resveratrol | Dietary Supplement: RGC<br> <br> |
| Active Comparator: Resveratrol<br>The equivalent of 150 mg resveratrol | Dietary Supplement: Resveratrol<br>* The equivalent of 150 mg resveratrol<br>* Other names: Transmax (Biotivia Ltd.);|
| Experimental: RGC2<br>RGC containing the equivalent of 150 mg resveratrol | Dietary Supplement: RGC<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Individual plasma concentrations of free and conjugated resveratrol | Pharmacokinetic data such as the peak plasma concentration (Cmax), time to peak (Tmax) ans area under the concentration-time curves (AUCt) will be reported. | 24 hours |
Bilateral and Unilateral Horizontal Strabismus Surgery

Study Overview
=================
Brief Summary
-----------------
This study was done in alternating strabismus patients to compare symmetrical muscle surgery and asymmetrical one as regard efficacy and lateral incomitance after surgery

Official Title
-----------------
Assessment of Symmetrical and Asymmetrical Horizontal Strabismus Surgery: Efficacy and Lateral Incomitance

Conditions
-----------------
Strabismus

Intervention / Treatment
-----------------
* Procedure: symmetrical and asymmetrical horizontal strabismus surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more than 3 years old. alternating esotropia or exotropia Exclusion Criteria: unilateral strabismus paralytic or restrictive strabismus

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 28 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Asymmetrical surgery<br>This asymmetrical horizontal muscle surgery done as recess-resect in one eye or 3 muscle surgery | Procedure: symmetrical and asymmetrical horizontal strabismus surgery<br>* surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye<br>|
| Active Comparator: Symmetrical<br>This symmetrical horizontal muscle surgery includes bilateral medial rectus recession in esotropia cases or bilateral lateral rectus recession in exotropia | Procedure: symmetrical and asymmetrical horizontal strabismus surgery<br>* surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| There was 95% success rate in asymmetrical group compared with 90% in symmetrical one | This result was measured by simultaneous prism cover test and expressed in prism diopter | one and half year |
Acceptance of Complementary Medicine in Germany

Study Overview
=================
Brief Summary
-----------------
Complementary medicine is widely practiced in Germany and worldwide. The aim of this study is to explore how many people use complementary medicine methods in Germany, for which health-related issues they do and for which they would not.

Official Title
-----------------
Acceptance of Complementary Medicine in Germany - an Anonymous Representative Cross-sectional Study Including a Qualitative Survey

Conditions
-----------------
General Population

Intervention / Treatment
-----------------
* Other: Cross-sectional survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent Age at least 18 years Sufficient language skills as well as cognitive ability to participate in an online survey or interview lasting approximately 30 minutes Active consent to the online consent form Exclusion Criteria: - Lack of consent to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Online survey with 3.000 participants using mobile website technology<br> | Other: Cross-sectional survey<br>* No intervention.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of attitudes towards complementary medicine | Assessed retrospectively with self-designed questions | Up to 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sociodemographic Parameters | Assessed retrospectively with self-designed questions | Up to 24 weeks | 
| Assessment of knowledge of complementary medicine | Assessed retrospectively with self-designed questions | Up to 24 weeks | 
| Assessment of own application of complementary medicine | Assessed retrospectively with self-designed questions | Up to 24 weeks | 
| Assessment of medical history and quality of life by EQ-5D-5L | Assessed retrospectively with self-designed questions | Up to 24 weeks | 
| Assessment of attitudinal and behavioral questions (e.g. lifestyle) | Assessed retrospectively with self-designed questions | Up to 24 weeks | 
| Assessment of use of complementary medicine in the Covid-19 pandemic | Assessed retrospectively with self-designed questions | Up to 24 weeks |